Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
← catalyst calendarNCT06608927 · readout in 1,564 d
Sponsored by Arcus Biosciences, Inc. (industry) · RCUS — their whole pipeline →. With Taiho Pharmaceutical Co., Ltd..
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
610estimated
Sites
111
Countries
Australia, Austria, Belgium +10
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-12-13 | actual | When the study began enrolling |
| Primary completion | 2030-11-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2030-11-30 | estimated | The whole study's end, after follow-up |
| First posted | 2024-09-23 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-31 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Metastatic Pancreatic Ductal Adenocarcinoma
Interventions
- Drug: Quemliclustat
- Drug: Placebo
- Drug: Nab-paclitaxel
- Drug: Gemcitabine
Primary outcome
what the primary-completion date above is the date OFOverall Survival (OS)
measured Up to 72 months
Permalink · RCUS's whole pipeline · Catalyst calendar · Every registered study · What changed